Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a major cause of juvenile sudden death and is characterized by fibro-fatty replacement of the right ventricle. Mutations in several genes encoding desmosomal proteins have been identified in ARVC. We speculated that aT-catenin, encoded by CTNNA3, might also carry mutations in ARVC patients. Alpha-T-catenin binds plakophilins and this binding contributes to the formation of the area composita, which strengthens cell-cell adhesion in contractile cardiomyocytes.
Introduction
Arrhythmogenic right ventricular cardiomyopathy (ARVC) (MIM # 107970) is an inherited cardiac disease characterized by progressive fibro-fatty myocardial replacement, primarily of the right ventricle. The main clinical features are structural and functional abnormalities of the ventricles, electrocardiographic depolarization/repolarization changes, re-entrant arrhythmias, and sudden death.
Most of the pathogenic mutations in ARVC have been identified in genes encoding the desmosomal proteins plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmocollin-2 (DSC2). 4 -11 Mutations in desmosomal genes have been identified in 50% of the ARVC patients, 12 defining desmosomes as major factors in ARVC pathogenesis.
A recently described cardiac junction is the so-called area composita, which is a mixed-type junctional structure composed of both desmosomal and adherens junctional proteins. 13 In epithelial cells, adherens junctions provide specific cell -cell adhesion by linking E-cadherin to the actin cytoskeleton. 14 The cytoplasmic domain of E-cadherin binds the armadillo proteins b-catenin and plakoglobin, which in turn bind a-catenins. Alpha-catenins are cytoplasmic molecules thought to be indispensable for dynamic maintenance of tissue morphogenesis by integrating in the cadherin-catenin complex and by interacting with the F-actin cytoskeleton. 15 -17 There are three a-catenin subtypes in mammals: the ubiquitously expressed aE-catenin, the neural aN-catenin, and aT-catenin, which is especially abundant in heart tissue and in the peritubular myoid cells of testis. 18 Both aT-catenin and aE-catenin are present in the area composita at the cardiac intercalated discs (ICD), as well as Ncadherin, one of the classic cadherins. Using yeast two-hybrid (Y2H) assays and co-immunoprecipitation, aT-catenin was shown to interact directly with PKP2, indicating a unique molecular amalgamation of adherens junctional and desmosomal proteins in the area composita. 19 From this we speculated that mutations in CTNNA3, the gene encoding aT-catenin, may also cause ARVC.
Methods

Clinical evaluation
The study involved 76 index patients of Italian descent diagnosed with ARVC according to major and minor criteria established by the 2010 Task Force. 20 The control group consisted of 250 healthy and unrelated Italian volunteers (500 alleles). Clinical evaluation consisted of a detailed personal and family history, physical examination, 12-lead electrocardiogram (ECG), signal-averaged ECG (SAECG), 24-h Holter ECG, stress test, and two-dimensional echocardiography.
Mutation screening
Mutation screening of the CTNNA3 gene was performed by denaturing high-performance liquid chromatography (DHPLC) and direct sequencing on 76 Italian index patients (52 males). Prior genetic studies excluded mutations in the ARVC genes PKP2, DSP, DSG2, DSC2, and JUP (data not shown). Recruitment, examination, and procedures for collection of DNA samples were in accordance with the Declaration of Helsinki. All participating individuals gave informed written consent. Polymerase chain reaction primers flanking each exon of the human CTNNA3 gene were designed by PRIMER3. Polymerase chain reaction primers and DHPLC conditions are described in Supplementary material online, Table S1 . The amplicons were analysed by DHPLC using the WAVE Nucleic Acid Fragment Analysis System 3500HT (Transgenomic Ltd, NE, USA). Samples showing changes in a DHPLC pattern were directly sequenced. CTNNA3 sequences were assembled, translated with SeqMan II (DNASTAR) and compared with a reference sequence NM_013266.
The control group was used to exclude the possibility that any detected variations are common DNA polymorphisms. All the controls were unrelated healthy volunteers from the general Italian population. Mutation screening was also performed on available family members of the probands in whom a CTNNA3 mutation was detected.
A one-sided binomial test was performed to compare the percentage of patients carrying CTNNA3 mutations relative to controls.
Construction of WT and mutant CTNNA3 vectors
The Gateway entry clone pENTR207-haTctn(179-2887) has been described. 19 Polymerase chain reaction-based site-directed mutagenesis was performed to obtain constructs with CTNNA3 cDNA carrying the mutations p.V94D and p.del765L (for details, see Supplementary material online). The Gateway entry clones pENTR207-haTctn(179-2887_WT), pENTR207-haTctn(179-2887_V94D), and pENTR207-haTctn(179-2887_ del765L) were transferred to pdGBKT7, pdGADT7, and pdEGFP by Gateway LR cloning (Invitrogen) to generate expression plasmids.
Yeast two-hybrid assay
The Matchmaker Gold Y2H system (Clontech) was used with the Y2HGold yeast strain for protein interaction tests. Cotransformants were obtained by standard methods, 21 and plated on minimal synthetic drop-out medium (SD) lacking leucine and tryptophan (SD -LW). After 3 days, colonies were picked and grown overnight in the SD -LW medium. Replica plates selecting for prey-bait interactions in transformed yeasts were made in SD medium lacking leucine, tryptophan, histidine, and alanine (SD -LWHA), but containing 70 mM potassium phosphate, and 50, 100, or 200 ng/mL Aureobasidin (AbA; Clontech). In some cases, 40 mg/mL 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-GAL, Clontech) was added. For every assay, expression levels of both bait and prey proteins were analysed by immunoblotting (see below).
Cell cultures
For cell culture assays, mutagenised cDNA was transfected into HL-1 cardiac myocytes, neonatal rat cardiomyocytes, HEK293T, and MCF7/ AZ cells. Neonatal rat cardiomyocytes were isolated from Crl:(WI)BR-Wistar rats (Charles River Laboratories, Wilmington, MA, USA) at the age of 1 -3 days as described. 22 All animal procedures were in accordance with the institutional guidelines for animal research. HL-1 cells, kindly provided by Dr W.C. Claycomb (New Orleans), were cultivated in Claycomb medium (Sigma) (for details, see Supplementary material online).
Transient transfection of cultured cells and immunofluorescent staining
Neonatal rat cardiomyocytes were transfected, by using TransFectin (Bio-Rad), with constructs expressing fusion proteins of enhanced green fluorescent protein (EGFP) with wild type (WT) aT-catenin, p.V94D mutant, or p.del765L mutant. HL-1 cells were transfected by using Lipofectamine 2000 (Invitrogen), MCF7/AZ cells were transfected with Fugene (Roche), and HEK293T cells were transfected by DNA calcium phosphate coprecipitation. The cells were fixed and incubated with mouse monoclonal antibody anti-b-catenin (clone 6F9, Sigma, diluted 1:150) and anti-vimentin (clone V9, Dako, diluted 1:500). After thorough rinsing of the coverslips in PBS, rabbit anti-mouse-TRITC (Dako) or goat anti-mouseAlexa 633 (Invitrogen) secondary antibody was applied. For aggresome detection, HEK293T cells were stained with the ProteoStat Aggresome dye (Enzo Life Sciences, PA, USA).
Immunoblot analysis of yeast and HEK293T cell cultures
Proteins were extracted from 2 OD 600 units of yeast cells. 23 Proteins were separated by SDS -PAGE and then immunoblotted with a polyclonal antibody raised against aT-catenin (rabbit pAb 952).
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Blots were developed with enhanced chemiluminescence and autoradiography.
Proteins from transfected HEK293T cells were isolated by boiling for 5 min in Laemmli buffer, or by using RadioImmunoPrecipitation Assay buffer. Immunoblot bands were quantified using the Odyssey system from Li-Cor Biotechnology (Lincoln, NE, USA) (for details, see Supplementary material online).
Co-immunoprecipitation
Cell lysates were prepared in PBS containing 1% Nonidet P-40 and a protease inhibitor cocktail (Complete; Roche Diagnostics). The lysates were centrifuged and a sample containing 800 mg protein was incubated for 4 h with a GFP-specific polyclonal antibody (3E6, Invitrogen) or b-catenin-specific monoclonal antibody (cl14, BD, Transduction Laboratories), after which 50 mL of anti-mouse IgG Dynabeads (Invitrogen) was added. After incubation for 1 h, the beads were washed four times with lysis buffer diluted 1/10. Samples were analysed by SDS-PAGE and western blotting. Proteins were detected with primary monoclonal anti-GFP antibody (Roche) or polyclonal anti-b-catenin antibody (Sigma), followed by horseradish peroxidasecoupled anti-mouse Ig or anti-rabbit Ig secondary antibody (Amersham), and blots were developed with enhanced chemiluminescence.
Results
Detection of CTNNA3 mutations
We performed an exon-by-exon analysis of the CTNNA3 gene on 76 ARVC index patients (52 males, mean age 42 + 12 years) who fulfilled the 2010 Task Force criteria for ARVC. 20 All patients were Figure 1 Family pedigrees of the patients with a CTNNA3 gene mutation.
Mutations in CTNNA3
negative for mutations in the ARVC genes PKP2, DSP, DSG2, DSC2, and JUP. Two novel heterozygous mutations (c.281T . A and c.2293_2295delTTG) of CTNNA3 were identified in two probands ( Figure 1 ). These variants were not found in 250 ethnically matched healthy controls (500 chromosomes), in dbSNP (http://www.ncbi .nlm.nih.gov/projects/SNP/), in the 1000 Genomes Project database (http://www.1000genomes.org), or in the Exome Variant Server (http://evs.gs.washington.edu/EVS/). The frequency of CTNNA3 mutation carriers in the 76 ARVC probands was 2.6% (95% CI: 0.0032-0.091; P-value for difference from the 250 Italian healthy controls ¼ 0.04; P-value for difference from all the data available in the above-mentioned databases ,2.2 × 10
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; binomial test, one-sided). The nucleotide substitution c.281T . A causes the amino acid change p.V94D, which was considered intolerant by SIFT (http://sift.jcvi.org/) and PolyPhen-2 (http ://genetics.bwh.harvard.edu/pph2/)
analysis. The variation c.2293_2295delTTG causes the deletion of leucine in position 765 (p.del765L). The missense mutation and the deletion are the first ARVC-associated CTNNA3 mutations to be reported. They are both localized in important domains of aT-catenin, and the affected residues are strongly conserved among species (see Supplementary material online, Figure S1 ).
Clinical findings
In family A, male proband II,1 ( Figure 1 ) was diagnosed at the age of 14 years during a screening for participation in sports activities. Basal ECG showed the presence of first degree atrioventricular block and negative T-waves in V1 -V4 in the absence of complete right bundle-branch block (QRS ≥ 120 ms) ( Figure 2 and Table 1) . He had several episodes of sustained ventricular tachycardia with left bundle-branch block (LBBB) morphology and superior axis deviation ( Figure 2 and Table 1 ). Late potentials were detected at 25, 40, and 80 filter setting, in the absence of a QRS duration ≥110 ms. Two-dimensional echocardiogram showed severe dilatation of the right ventricle with marked hypokinesia of the free wall, reduced right ventricular ejection fraction (RVEF), and anterior, apical and subtricuspid akinesia. Moreover, magnetic resonance imaging (MRI) showed a marked dilatation of the right ventricle, apical sacculation, and regional right ventricle akinesia with the RVEF of 30% ( Figure 2 and Table 1 ). After three transcatheter ablations, the patient received an implantable cardioverter defibrillator at the age of 36 years. The parents (I,1; I,2) and the brother (II,3) ( Figure 1) were fully asymptomatic and do not carry the p.V94D mutation. Of note, the family history and genetic testing did not provide evidence that the cardiomyopathy of the proband was inherited.
Female proband III,3 in family B ( Figure 1 ) was examined at the age of 15 years due to a syncopal episode. The ECG Holter showed non-sustained ventricular tachycardia with LBBB morphology and superior axis. Moreover, late potentials were present at 40 and 80 filter settings, in the absence of a QRS duration of ≥110 ms. Echocardiography showed mild right ventricular dilatation with kinetic abnormalities in the apical region ( Table 1) . Magnetic resonance imaging confirmed the presence of a mild dilatation of the right ventricle together with kinetic alterations of the right ventricular apex. She is currently undergoing antiarrhythmic therapy with Sotalol. Her father (II,5) (Figure 1) , who carries the same mutation, does not fulfil the current diagnostic criteria for ARVC, but his echocardiogram demonstrates a mild right ventricular dilatation (PLAX RVOT ¼ 30 mm). Subject II,3 (Figure 1) carries the p.del765L mutation and was asymptomatic, but contrast-enhanced MRI showed increased trabeculations in the right ventricular apex and intramural and epicardial fibrosis in the left ventricular posterolateral and basal inferior wall. Subject I,2 ( Figure 1 ) died at the age of 83 years due to heart failure, without a history of valvular or ischaemic cardiac disease. Subject III,2 (Figure 1) , who carries the same mutation, was asymptomatic, in line with the incomplete penetrance of the disease. 24 Differential binding of WT and mutated aT-catenin Alpha-T-catenin can interact with plakophilins PKP1, PKP2, and PKP3. 19 These interactions were confirmed in an improved Y2H assay (Matchmaker Gold, Clontech) ( Figure 3A , rows 1 and 4).
Interactions between aT-catenin and b-catenin or plakoglobin were also confirmed ( Figure 3A , rows 7 and 10). In the same assay, the p.V94D and p.del765L mutants interacted normally with PKP3 and PKP2 ( Figure 3A , rows 2, 3, 5, and 6). In contrast, the interaction of the p.V94D mutant with b-catenin or plakoglobin was quite weak compared with WT ( Figure 3A , rows 8 and 11), whereas the p.del765L mutant still interacted normally with these armadillo proteins ( Figure 3A , rows 9 and 12). The b-catenin binding site of the related human aE-catenin comprises residues 54 -148 (see Supplementary material online, Figure S1A ).
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Next, to test in mammalian cells whether the interaction of the p.V94D mutant with b-catenin was weaker than the WT interaction, endogenous b-catenin in HEK293T cells was co-immunoprecipitated with exogenous GFP -aT-catenin fusion protein ( Figure 4A , left part). Co-immunoprecipitation was also done in the other direction ( Figure 4A, right part) . In both experimental setups, the interaction between p.V94D proteins and fulllength b-catenin was much diminished.
Also homodimerization of aT-catenin was assessed in the Gold Y2H assay. The relative ability of Gold Y2H strains to grow in the presence of increasing concentrations of AbA reflects the strength of the interaction between bait and prey proteins. The homodimerization potentials of WT aT-catenin and p.V94D seemed rather weak because higher levels of AbA in the growth medium prevented yeast growth ( Figure 3B , rows 1 and 2, columns C -E). In contrast, p.del765L showed a much stronger homodimerization potential than WT ( Figure 3B, row 3) . As the ARVC probands are heterozygous for their CTNNA3 mutation, we also checked the interaction between the mutants and WT aT-catenin ( Figure 3B , rows 4-7). We found that this interaction as well was stronger for the p.del765L mutant. This feature could lead to a dominant negative or dominant positive effect of p.del765L. We also tested whether aT-catenin interacts with aE-catenin, but neither WT nor mutant aT-catenin showed detectable interaction with aE-catenin in the Y2H assay (data not shown). 
Mutations in CTNNA3
Cellular localization of aT-catenin
To assess whether the p.V94D and p.del765L mutations affect subcellular localization of aT-catenin, we expressed WT aT-catenin and the mutants as EGFP-fusion proteins. Constructs were transiently transfected into neonatal rat cardiomyocytes ( Figure 4B ) and into the mouse cardiac muscle cell line HL-1 (see Supplementary material online, Figure S2 ). In both cell types, WT and mutant p.del765L fusion proteins were detected at cell -cell contacts, where they colocalized with endogenous b-catenin. In contrast, the fusion protein carrying the p.V94D mutation was predominantly and consistently localized in the cytoplasm. No difference in the distribution of plakoglobin, plakophilin-2, or F-actin was observed (data not shown).
In addition, we took advantage of the capacity of overexpressed exogenous aT-catenin to form thread-shaped structures in MCF7/ AZ cells (see Supplementary material online, Figure S3 ). This capacity was preserved in the p.V94D mutant. The amino-terminal part of b-catenin colocalized with the threads formed by WT aT-catenin but not with the threads containing the p.V94D mutation, confirming in mammalian cells that the interaction of the p.V94D mutant protein with b-catenin is crippled.
The stronger dimerization potential of p.del765L in yeast could mean that it is more stable than WT aT-catenin. In transformed yeast cells, chimaeric GAL4-aT-catenin protein levels were, however, similar for WT, p.V94D, and p.del765L (data not shown). We then addressed protein stability by cycloheximide treatment of transfected HEK293T cells. We noticed no differences in stability (data not shown), but the amount of solubilized p.del765L turned out to be strikingly less in RIPA lysates than in Laemmli buffer lysates ( Figure 5A) . Interestingly, microscopic evaluation of HEK293T transfectants revealed that the p.del765L mutant protein had an aggregate-like appearance unlike WT or p.V94D proteins ( Figure 5B and 5C) . Apparently, these p.del765L aggregates were less soluble in RIPA buffer. They fulfilled all criteria of aggresomes 26 by being pericentriolar structures different from ER, Golgi, and lysosomes, and recruiting a so-called vimentin cage ( Figure 5D ). The p.del765L aggregates also stained positive for Proteostat, an amyloid-specific red fluorescent dye ( Figure 5E ). 27 Recent evidence indicates that the mechanisms involved in the assembly of cytoplasmic protein aggresomes might differ in different cell lines. 28 Indeed, we did not observe prominent aggregates of this type in several other cell lines transfected with p.del765L. We also noticed that the WT protein was present in the aggresomes if the HEK293T cells expressed both WT and p.del765L protein ( Figure 5F ).
Discussion
We provide here the first description of aT-catenin mutations associated with a human disease. The two probands we identified fulfil the current ARVC diagnostic criteria and their clinical phenotype is identical to that reported in ARVC patients carrying typical desmosomal gene mutations. However, in the heart, aT-catenin is present only in the areae compositae. 19 In a previous study, the CTNNA3 gene was evaluated in a family with dilated cardiomyopathy showing linkage to chromosomal region 10q21, but no CTNNA3 mutations were detected. 29 More recently, Christensen et al. 30 performed mutation screening on 55 Danish patients fulfilling ARVC diagnostic criteria and found the rare p.A689V variant of CTNNA3 in one patient, but they considered that the significance of this variant is unknown because they also found it in 2 out of 1400 controls. It is not clear exactly how the CTNNA3 mutations we report here perturb the assembly and function of the areae compositae in ARVC hearts. Germline knockout of aT-catenin in the mouse alters PKP2 distribution without affecting other junctional components of the areae compositae. 31 These mutant mice exhibit progressive dilated cardiomyopathy, gap junction remodelling, and increased sensitivity to ventricular arrhythmia following acute ischaemia, but not spontaneous ARVC. We speculate that the expression in cardiomyocytes of the mutant aT-catenins reported here might have a more drastic effect than full abrogation of aT-catenin. Mutant aT-catenins might lead to much weakened junctions between adjacent cardiomyocytes and to disruption of tissue integrity, particularly in response to excessive mechanical stress (e.g. competitive sports). This pathogenetic hypothesis would also explain why ARVC mostly involves the thin-walled areas of the right ventricle, which are structurally more vulnerable to mechanical stress. 
Mutations in CTNNA3
Each of the two mutations reported here affects crucial functions of aT-catenins. Mutant p.V94D protein interacts only weakly with b-catenin and plakoglobin, whereas the dimerization potential of mutant protein p.del765L is abnormally high, as shown by Y2H experiments and formation of aggresomes in transfected HEK293T cells. Though no studies on aT-catenin dimers vs. monomers have been reported, homodimeric forms of aE-catenin have been shown to bind to F-actin, whereas monomeric forms bind with greater strength to E-cadherin -b-catenin complexes. 17 We presume that in cardiomyocytes expressing the p.V94D or p.del765L mutant, higher levels of aT-catenin might be present in dimeric form outside the area composita. Moreover, as the mutant proteins can also heterodimerize with WT aT-catenin, they are expected to compete with the binding of WT aT-catenin to b-catenin and PKP2 within the area composita. We speculate that this might perturb F-actin organization at the ICD and simultaneously cause PKP2 to redistribute along the ICD. Our data indicate that aT-catenin cannot heterodimerize with aE-catenin, but the functionality of aE-catenin in the area composita might be indirectly affected by the change in F-actin dynamics owing to excessive aT-catenin dimerization. Nonetheless, the detailed expression patterns of various junctional components, including PKP2, in cardiomyocytes expressing aT-catenin mutations require further studies at higher resolution on more relevant material, i.e. endomyocardial biopsies or transgenic mouse models. Moreover, on the basis of the aT-catenin expression pattern and its specific function in the ICD, and in view of the Ctnna3-null mice phenotype, we expect that mutations in the CTNNA3 gene will lead to a cardiac abnormality in humans. However, though our results provide evidence for the pathogenic role of the detected mutations, a limitation of the present study is the lack of the in vivo demonstration of their causative role. The proof of a causal relationship between CTNNA3 mutations and ARVC awaits the generation and analysis of appropriate animal models, including knock-in mice for the various Ctnna3 mutations.
In conclusion, our findings suggest a causal relationship between CTNNA3 mutations and the ARVC pathology. The identification of a new gene involved in ARVC has major clinical implications. Since the frequency of CTNNA3 mutations in ARVC patients is not rare, systematic screening for this gene should be considered to improve the management of ARVC families, through early diagnosis and genetic-based cardiac screening and follow-up in relatives. Most mutations known to cause ARVC are in JUP, DSP, PKP2, DSG2, and DSC2, all of which encode proteins present in both desmosomes and areae compositae. 13 As aT-catenin is present only in areae compositae but not in desmosomes, ARVC could be considered a disease of the area composita rather than a classical desmosomal disease. Details of the role of aT-catenin in the ICD in vivo and of the behaviour of the mutant aT-catenin proteins identified in ARVC patients remain challenging topics of further study.
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